AMY DE LA ROSA: Open Payments
NPI 1972730513 · BEDFORD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,007 in 106 payments from 16 companies in 2025. Trend: 2023 $1,270 · 2024 $1,860 · 2025 $2,007
Food & beverage: $1,838Education: $169
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $347 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $314 |
| Janssen Biotech, Inc. | 9 | $292 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $194 |
| Phathom Pharmaceuticals, Inc. | 10 | $190 |
| Regeneron Healthcare Solutions, Inc. | 9 | $173 |
| QOL Medical, LLC | 5 | $163 |
| GENZYME CORPORATION | 3 | $88 |
| Ardelyx, Inc. | 4 | $65 |
| Celltrion USA Inc. | 3 | $48 |
Products named: TREMFYA, DUPIXENT, ENTYVIO, VOQUEZNA, RINVOQ, XIFAXAN, Sucraid, GATTEX.
Industry payments across TX — which companies pay providers there.
